Download Databook
Download Sample
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The multiple modalities in oncology market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
The increasing incidence of cancers, as well as their heterogeneity, are increasing the demand for multiple modalities. Thus, to develop new approaches, various partnerships are being established. Additionally, the use of AI for improving the diagnosis is also increasing. At the same time, various combination therapies are also being developed as well as used. The different regions are also contributing to these rising developments. Furthermore, new products are also being launched. Thus, all these factors are enhancing the multiple modalities in oncology market growth.
Cancer is considered a heterogeneous disease, where new therapeutic modalities like immunotherapy, advancements in surgical techniques, and targeted therapy are required to improve cancer treatment. Hence, multiple modalities in oncology involve the combination of various treatment approaches such as chemotherapy, targeted therapy, surgery, immunotherapy, radiotherapy, and newer biological therapies. This combination of modalities is used to achieve complete control over cancer. Depending on the cancer molecular profile, characteristics, and stage, the combination and the sequence of these modalities are developed, where each of them has its unique roles.
For the development of various methods, strategies, and modalities, the use of AI is increasing in multiple modalities in oncology. With the help of AI, a single modality can be effectively operated. At the same time, data of different modalities can also be merged, which can improve the accuracy of the prognostic and diagnostic models. Moreover, the different patient outcomes and resistance to treatment can be explained by discovering novel patterns in these modalities. Thus, this enhances the development of new strategies and methods with the help of AI.
Growing Tumor Heterogeneity
The rising incidence of cancer is increasing the tumor heterogeneity within the population. This, in turn, increases the resistance of the tumor cell. Thus, the demand for multiple modalities to eradicate these tumors is rising. Therefore, with their help, the different pathways involved in heterogeneous tumors can be blocked. At the same time, combination therapies can help in stimulating or enhancing the immune cells to attack these tumor cells. Hence, all the growing tumor heterogeneity drives the multiple modalities in oncology market growth.
High Cost
The multiple modalities for cancer treatment involve the combination of various treatment approaches. This, in turn, increases the cost depending on the combination that is to be used. At the same time, it becomes difficult for the patient to afford them due to low income. This results in limited access by the patients, causing a restraint on the market growth.
Increasing Treatment Approaches
Various new treatment approaches are being developed due to growing interest in multiple modalities in the field of oncology. New personalized multiple modality regimens are being developed. At the same time, various new combinations of immunotherapies are also driving the research and development. Moreover, new targeted drug combinations are also being developed. Additionally, various approaches are also being developed to enhance the safety and efficacy of the treatment. Thus, these new developments promote the multiple modalities in oncology market growth.
For instance,
By modality type, the chemotherapy segment held the largest share in the multiple modalities in oncology market in 2024. The chemotherapy was a preferred option as it was used in a variety of cancers along with different multimodal regimens. Thus, this contributed to the market growth.
By modality type, the immunotherapy segment is expected to show the highest growth at a notable CAGR during the predicted time. The use of immunotherapy is growing due to its enhanced outcomes with other modalities and reduced toxicity.
By cancer type, the breast cancer segment led the multiple modalities in oncology market in 2024. A large number of breast cancer cases, as well as growing awareness, have increased the use of multiple modalities in the early stages, which has enhanced the market growth.
By cancer type, the lung cancer segment is expected to show the fastest growth during the upcoming years. The use of multiple modalities in the effective treatment of lung cancer is increasing due to their growing incidence and early detection.
The graph represents the estimated number of lung cancer cases in the U.S. in year of 2025. It indicates that there will be a rise in cases of lung cancer. Hence, it increases the demand for multiple modalities options for its effective management. Thus, this in turn will ultimately promote the market growth.
By the combination approach type, the chemo + immunotherapy segment held the major share in the multiple modalities in oncology market in 2024. The chemo + immunotherapy was used in a variety of cancer types as it enhanced the patient outcomes by eliminating the cancer cells and improving the immune response.
By the combination approach type, the radiation + immunotherapy segment is expected to show the highest growth during the predicted time. The use of radiation + immunotherapy in early stages is increasing as it enhances the immune responses against cancer, as well as in patients with an insufficient response to single modality treatment.
By end user, the hospitals segment held the dominating share in the global multiple modalities in oncology market in 2024. The hospitals provided a wide range of multiple modalities treatment approaches for cancer patients. At the same time, personalized treatment approaches were also provided, which promoted the market growth.
By end user, the cancer research institutes segment is expected to show the fastest growth during the upcoming years. The cancer research institutes are focusing on the development of new modalities, combinations, as well as personalized treatment approaches.
North America dominated the multiple modalities in oncology market in 2024. North America consisted of a well-developed healthcare sector, which offered advanced multiple modalities for cancer treatment. Thus, this promotes the market growth.
Multiple cancer centers in the U.S are using various modalities for providing effective treatment to cancer patients. At the same time, new combinations to enhance this multimodal care are also being developed with the help of advanced technologies.
The presence of advanced healthcare in Canada is increasing the use of multiple modalities in cancer. At the same time, these treatment approaches are being supported by investments provided by private or government sectors.
Asia Pacific is expected to host the fastest-growing multiple modalities in oncology market during the forecast period. The increasing cancer incidences in the Asia Pacific are increasing the use of multiple modalities for their treatment. Thus, this enhances the market growth.
The cancer cases in China are increasing. At the same time, the adoption of advanced technologies as well as the development in multiple modalities for cancer are rising. Thus, these advanced new regimens are enhancing the safety profile of the treatment approaches.
The growing incidence of cancer in India is increasing the demand for multiple modalities. Furthermore, new personalized treatment approaches as well as regimens are being developed to improve the multimodal care, at an affordable price, with government investments.
For instance,
Europe is expected to grow significantly in the multiple modalities in oncology market during the forecast period. The presence of a strong healthcare sector in Europe is increasing the use of multiple modalities for cancer treatment. This, in turn, promotes the market growth.
The use of multiple modalities in Germany is growing due to the robust healthcare sector. At the same time, the ease of access for these modalities is provided by the healthcare sector. This, in turn, is enhancing the patient outcomes.
The research and development in the UK for various modalities in the field of cancer are rising. This, in turn, increases the clinical trials with growing approvals for new modalities, which in turn are supported by the regulatory bodies.
By Modality Type
By Cancer Type
By Combination Approach
By End User
By Region
June 2025
June 2025
June 2025
June 2025